Lonza has launched a reformulated CHO media that it says supports the growth of higher density cultures and is easier to filter than currently available products.
Life Technologies has concluded license agreements, providing rights to its proprietary Chinese hamster ovary (CHO) cell lines for production of recombinant proteins used as therapeutic agents and vaccines.